Manuel Alba, serving as a director at Astera Labs, Inc. (NASDAQ: ALAB), completed a significant divestment of company equity on July 1, 2026. The transaction involved the sale of common stock valued at $16,792,741. The shares were liquidated at prices ranging from $429.5782 to $467.9952 per share, reflecting the premium valuation the market has assigned to the semiconductor connectivity provider over the past twelve months.
The execution of this sale follows a structured timeline established under a Rule 10b5-1 trading plan. Mr. Alba originally adopted this plan on May 29, 2025, a mechanism typically used to automate sales and mitigate regulatory scrutiny regarding insider trading timing. The total volume of the transaction comprised 36,837 shares of common stock, distributed across multiple trades.
Analysis of the beneficial ownership structure reveals that the sales were not executed directly by Mr. Alba personally, but rather through affiliated entities. Specifically, 13,026 shares were sold indirectly by the Alba Trust. Mr. Alba and his spouse serve as co-trustees of this entity, establishing a direct fiduciary link to the transaction. The remaining 23,811 shares were liquidated through Casa Alameda 2007, LLC, a limited liability company for which Mr. Alba holds a managerial role. Despite these indirect sales, Mr. Alba has formally disclaimed beneficial ownership of the securities, limiting his claim to the extent of his pecuniary interest in the entities involved.
The timing of this divestment is notable given the stock's recent performance trajectory. Over the past year, ALAB shares have delivered a substantial 383% return, a figure that underscores the market's aggressive pricing of the company's position in the AI infrastructure supply chain. However, this long-term appreciation has been tempered by recent volatility; shares have declined 10% over the last week. According to InvestingPro analysis, ALAB currently appears overvalued relative to its calculated Fair Value, placing it among stocks identified on the Most Overvalued list.
The sale comes amid a complex landscape of analyst sentiment and corporate governance updates. UBS recently raised financial estimates for both Marvell Technology and Astera Labs, emphasizing the expanding opportunity within Compute Express Link (CXL) technology. While UBS maintained a Buy rating on Marvell, it kept a Neutral rating on Astera Labs, adjusting its price target to $400. Conversely, Stifel reiterated its Buy rating for Astera Labs following investor meetings, setting a price target of $260. Northland, however, downgraded the stock to Market Perform, citing valuation concerns alongside broader fears of supply chain disruptions and declining AI infrastructure spending affecting the semiconductor sector.
Corporate governance proceedings also marked this period, with Astera Labs holding its 2026 Annual Stockholders Meeting. The meeting resulted in the election of three Class II directors to serve until the 2029 annual meeting. Shareholder participation was robust, with over 141 million shares voted, indicating high institutional and retail engagement in the company's strategic direction.